Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 4/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26643986 | 0.99 | L3MBTL1 (0.36) | L3MBTL1BRAFGSK3BDYRK1AALDH1A1 | |
| SCHEMBL31361604 | 0.84 | JAK2 (0.38) | L3MBTL1BRAFALDH1A1JAK2JAK1 | |
| SCHEMBL16985335 | 0.81 | ROCK2 (0.37) | L3MBTL1ALDH1A1PNMTF2PLAU | |
| SCHEMBL16985304 | 0.81 | ROCK2 (0.37) | L3MBTL1ALDH1A1PNMTF2PLAU | |
| SCHEMBL15317792 | 0.81 | ROCK2 (0.37) | L3MBTL1ALDH1A1PNMTF2PLAU | |
| Hydrochloric Acid SCHEMBL30475612 | 0.80 | CYP1A2 (0.38) | L3MBTL1ALDH1A1PNMTF2PLAU | |
| Hydrochloric Acid SCHEMBL20476166 | 0.80 | CYP1A2 (0.38) | L3MBTL1ALDH1A1PNMTF2PLAU | |
| Hydrochloric Acid SCHEMBL9951956 | 0.80 | CYP1A2 (0.38) | L3MBTL1ALDH1A1PNMTF2PLAU | |
| Trifluoroacetic Acid SCHEMBL29503617 | 0.78 | MET (0.34) | L3MBTL1ALDH1A1F2PLAUELANE | |
| SCHEMBL15709846 | 0.77 | CYP1A2 (0.43) | IRAK4F2PLAUELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025017116-A1 | PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20180354956-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-13 | — | — | US | disclosed |
| US-10087186-B2 | Compounds as LRRK2 kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-02 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | L3MBTL1 304/4885BRAF 1962/4885GSK3B 22/4885 |
| US-10087186-B2 | Compounds as LRRK2 kinase inhibitors | LRRK2, PINK1, PARK7 | L3MBTL1 457/4885BRAF 838/4885GSK3B 33/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | L3MBTL1 491/4885BRAF 1781/4885GSK3B 37/4885 |
| US-20180354956-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | L3MBTL1 491/4885BRAF 1781/4885GSK3B 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.